[MeS10] Medical Seminar 10　Neoadjuvant chemotherapy for HER2-positive breast cancer in the era of Residual disease-guided approach

[MeS10-1] Neoadjuvant chemotherapy for HER2-positive breast cancer in the era of Residual disease-guided approach

^○Tetsuhiro Yoshinami (Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital / Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University)